Cargando…
853. Epidemiology of Groups A, C, and G β-Hemolytic Streptococcal Pharyngitis
BACKGROUND: Treatment of Group A Streptococcus (GAS) pharyngitis is imperative to mitigate sequelae such as rheumatic heart disease. The need for treatment of Group C Streptococcus (GCS) and Group G Streptococcus (GGS) pharyngitis is unclear, as rheumatogenic sequelae have not been well documented....
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809185/ http://dx.doi.org/10.1093/ofid/ofz359.038 |
_version_ | 1783461923216424960 |
---|---|
author | Lim, James Ray Mata Boyanton, Bobby L George, Julie Sims, Matthew |
author_facet | Lim, James Ray Mata Boyanton, Bobby L George, Julie Sims, Matthew |
author_sort | Lim, James Ray Mata |
collection | PubMed |
description | BACKGROUND: Treatment of Group A Streptococcus (GAS) pharyngitis is imperative to mitigate sequelae such as rheumatic heart disease. The need for treatment of Group C Streptococcus (GCS) and Group G Streptococcus (GGS) pharyngitis is unclear, as rheumatogenic sequelae have not been well documented. Our institution switched from culture to molecular confirmation testing for a negative rapid streptococcal antigen detection test. Cultures reported GAS whereas molecular testing reported GAS, GCS, and GGS. We performed a retrospective chart review to examine the epidemiological differences of GAS, GCS, and GGS pharyngitis. METHODS: Records were obtained of pharyngeal samples from patients sent for testing at Beaumont Health Laboratory. In all, 92,369 records were analyzed. There were 47,106 records of cultures from May 2012 through December 2014 and 45,263 records of molecular testing from May 2015 to December 2017. Samples positive for either GCS or GGS were reported as positive for Group CG Streptococcus (GCGS). Epidemiological factors were evaluated. If available, electronic records from GCGS positive samples were evaluated for clinical features, antibiotics used, and sequelae or complications reported. RESULTS: Molecular testing showed GAS positivity of 9.3% (n = 4,189) and GCGS positivity of 1.5% (n = 687). GCGS pharyngitis was more likely during the summer months and in young adults 13 years and older than children under 13 years. GAS pharyngitis was more likely during spring months and in children aged 4–9 years. Mean age of GCGS pharyngitis was 13 vs. 8.6 years for GAS pharyngitis. Similar results were obtained for GAS between culture and molecular testing records. Amoxicillin was most often prescribed for treatment of GCGS. There were few instances of severe GCGS exudative or recurrent pharyngitis that required hospitalization or tonsillectomy. There were no cases of rheumatic fever or rheumatic heart disease associated with GCGS. CONCLUSION: This is the largest study based on our literature review to evaluate the epidemiology of GAS, GCS, and GGS pharyngitis in children and adults. We found a seasonal and age difference between GAS and GCGS. Complications were rare, and no rheumatogenic sequelae were noted from GCGS infections. [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All Authors: No reported Disclosures. |
format | Online Article Text |
id | pubmed-6809185 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-68091852019-10-28 853. Epidemiology of Groups A, C, and G β-Hemolytic Streptococcal Pharyngitis Lim, James Ray Mata Boyanton, Bobby L George, Julie Sims, Matthew Open Forum Infect Dis Abstracts BACKGROUND: Treatment of Group A Streptococcus (GAS) pharyngitis is imperative to mitigate sequelae such as rheumatic heart disease. The need for treatment of Group C Streptococcus (GCS) and Group G Streptococcus (GGS) pharyngitis is unclear, as rheumatogenic sequelae have not been well documented. Our institution switched from culture to molecular confirmation testing for a negative rapid streptococcal antigen detection test. Cultures reported GAS whereas molecular testing reported GAS, GCS, and GGS. We performed a retrospective chart review to examine the epidemiological differences of GAS, GCS, and GGS pharyngitis. METHODS: Records were obtained of pharyngeal samples from patients sent for testing at Beaumont Health Laboratory. In all, 92,369 records were analyzed. There were 47,106 records of cultures from May 2012 through December 2014 and 45,263 records of molecular testing from May 2015 to December 2017. Samples positive for either GCS or GGS were reported as positive for Group CG Streptococcus (GCGS). Epidemiological factors were evaluated. If available, electronic records from GCGS positive samples were evaluated for clinical features, antibiotics used, and sequelae or complications reported. RESULTS: Molecular testing showed GAS positivity of 9.3% (n = 4,189) and GCGS positivity of 1.5% (n = 687). GCGS pharyngitis was more likely during the summer months and in young adults 13 years and older than children under 13 years. GAS pharyngitis was more likely during spring months and in children aged 4–9 years. Mean age of GCGS pharyngitis was 13 vs. 8.6 years for GAS pharyngitis. Similar results were obtained for GAS between culture and molecular testing records. Amoxicillin was most often prescribed for treatment of GCGS. There were few instances of severe GCGS exudative or recurrent pharyngitis that required hospitalization or tonsillectomy. There were no cases of rheumatic fever or rheumatic heart disease associated with GCGS. CONCLUSION: This is the largest study based on our literature review to evaluate the epidemiology of GAS, GCS, and GGS pharyngitis in children and adults. We found a seasonal and age difference between GAS and GCGS. Complications were rare, and no rheumatogenic sequelae were noted from GCGS infections. [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All Authors: No reported Disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6809185/ http://dx.doi.org/10.1093/ofid/ofz359.038 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Lim, James Ray Mata Boyanton, Bobby L George, Julie Sims, Matthew 853. Epidemiology of Groups A, C, and G β-Hemolytic Streptococcal Pharyngitis |
title | 853. Epidemiology of Groups A, C, and G β-Hemolytic Streptococcal Pharyngitis |
title_full | 853. Epidemiology of Groups A, C, and G β-Hemolytic Streptococcal Pharyngitis |
title_fullStr | 853. Epidemiology of Groups A, C, and G β-Hemolytic Streptococcal Pharyngitis |
title_full_unstemmed | 853. Epidemiology of Groups A, C, and G β-Hemolytic Streptococcal Pharyngitis |
title_short | 853. Epidemiology of Groups A, C, and G β-Hemolytic Streptococcal Pharyngitis |
title_sort | 853. epidemiology of groups a, c, and g β-hemolytic streptococcal pharyngitis |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809185/ http://dx.doi.org/10.1093/ofid/ofz359.038 |
work_keys_str_mv | AT limjamesraymata 853epidemiologyofgroupsacandgbhemolyticstreptococcalpharyngitis AT boyantonbobbyl 853epidemiologyofgroupsacandgbhemolyticstreptococcalpharyngitis AT georgejulie 853epidemiologyofgroupsacandgbhemolyticstreptococcalpharyngitis AT simsmatthew 853epidemiologyofgroupsacandgbhemolyticstreptococcalpharyngitis |